Zacks Research Forecasts Lower Earnings for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Zacks Research reduced their Q4 2025 EPS estimates for shares of Gilead Sciences in a research report issued on Thursday, November 13th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of $1.81 for the quarter, down from their previous estimate of $1.82. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q1 2026 earnings at $1.69 EPS, Q2 2026 earnings at $1.80 EPS, Q3 2026 earnings at $2.32 EPS, Q4 2026 earnings at $2.31 EPS, FY2026 earnings at $8.13 EPS, Q1 2027 earnings at $1.97 EPS, Q2 2027 earnings at $2.14 EPS, Q3 2027 earnings at $2.55 EPS and FY2027 earnings at $9.04 EPS.

A number of other research firms also recently issued reports on GILD. Truist Financial restated a “buy” rating and set a $145.00 price objective (up previously from $127.00) on shares of Gilead Sciences in a report on Monday, November 3rd. Daiwa Capital Markets upped their price objective on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Rothschild & Co Redburn boosted their target price on Gilead Sciences from $143.00 to $153.00 in a research note on Monday. Finally, Royal Bank Of Canada increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $129.13.

Gilead Sciences Stock Performance

GILD stock traded down $1.94 during midday trading on Friday, hitting $123.26. The company’s stock had a trading volume of 1,871,631 shares, compared to its average volume of 7,940,996. The stock has a market cap of $152.93 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 0.81 and a beta of 0.32. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The stock’s 50-day moving average price is $117.24 and its 200 day moving average price is $112.64. Gilead Sciences has a 1 year low of $86.08 and a 1 year high of $127.68.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the sale, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 94,646 shares of company stock valued at $11,311,286 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Institutional Trading of Gilead Sciences

Several institutional investors have recently added to or reduced their stakes in the business. GoalVest Advisory LLC boosted its holdings in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences in the 3rd quarter worth about $26,000. Activest Wealth Management boosted its stake in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at about $27,000. Finally, Howard Hughes Medical Institute bought a new position in Gilead Sciences in the second quarter worth about $30,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.